louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00128089: Trial of New Dietary Treatment of Diabetes
Official title: Phase 1 Trial of A New Dietary Treatment of Obesity Related Type 2 Diabetes
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Diabetes Mellitus, Type 2
Keywords: Obesity
Dietary treatment
Fasting as medical therapy
Lead sponsor: Manassas Internal Medicine
Sponsor class: OTHER
First posted: 2005-08-09
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a preliminary trial of a new dietary approach to the treatment of obesity related type 2 diabetes.

Study terminated December 19, 2005 for administrative reasons.

Detailed description: Traditional dietary treatment of type 2 diabetes is complicated and often fails.

This is a dietary treatment that uses fingerstick testing of blood sugars and a remarkably simple algorithm to promptly lower the blood glucose to treatment goals.

A series of 10 overweight type 2 diabetic patients not well controlled, or needing medication for control, will be recruited to follow this plan; followup is to be until 6 months after the last patient is enrolled, or when all patients have normal A1Cs with no medication, whichever comes first.

Primary endpoints to be measured are A1C, weight loss (in pounds and BMI reduction) and medication reduction. Secondary endpoints are occurrences of hypoglycemia, reduction of medications for hypertension and hyperlipidemia, and patient satisfaction. As this is a Phase 1 trial, the only control group is historical controls (the patients themselves and the medical literature).

Eligibility criteria: Inclusion Criteria:

* Diabetes mellitus, type 2
* Obesity
* Ability to attend office visits in Manassas, Virginia

Exclusion Criteria:

* Dementia
* Institutionalized living
* Retinopathy, neuropathy
* Pregnancy
* Serious health problems such as heart disease or stroke

Primary outcomes:
measure: Glycated hemoglobin (A1C) changes
measure: Weight (body mass index [BMI]) loss
measure: Diabetes medication reduction
Secondary outcomes:
measure: Hypoglycemia
measure: Other medication reduction
measure: Patient satisfaction
Other outcomes:
Locations:
city: Manassas
country: United States
facility: Manassas Internal Medicine
state: Virginia
Study officials:
affiliation: Manassas Internal Medicine
name: John F Cary, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00011089: Tenofovir Disoproxil Fumarate in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drug Combinations
Official title: US Expanded Access Program of Tenofovir Disoproxil Fumarate in the Treatment of HIV-1 Infected Patients Who Have Limited Treatment Options
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: HIV Infections
Keywords: HIV-1
Disease Progression
Reverse Transcriptase Inhibitors
Anti-HIV Agents
9-(2-phosphonylmethoxypropyl)adenine
Lead sponsor: NIH AIDS Clinical Trials Information Service
Sponsor class: INDUSTRY
First posted: 2001-08-31
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to make tenofovir disoproxil fumarate (DF) available to HIV-infected patients who have failed other anti-HIV drug combinations, who have few treatment choices available, and whose disease may get worse. This study will allow patients to obtain tenofovir DF before it is approved for marketing.

Detailed description: Patients receive daily doses of tenofovir DF.

Eligibility criteria: Inclusion Criteria

Patients may be eligible for this study if they:

* Are HIV-positive.
* Have a viral load (level of HIV in the blood) of at least 10,000 copies/ml by PCR within the previous 2 months.
* Have a CD4 count of 100 cells/mm3 or lower within the previous 2 months. Patients with a CD4 count above 100 and as high as 200 cells/mm3 may also be eligible if they had an opportunistic (AIDS-related) infection within the past 90 days.
* Have failed treatment with at least 2 protease inhibitors (PIs) or at least 1 PI plus a nonnucleoside reverse transcriptase inhibitor (NNRTI).
* Are not able to get effective treatment with a combination of currently approved anti-HIV drugs.
* Are at least 18 years old.
* Have a negative serum pregnancy test.
* Are willing to use a barrier method of birth control (both males and females) while on the study and for 30 days after taking the drug.

Exclusion Criteria

Patients will not be eligible for this study if they:

* Have or have had kidney disease or bone disease.
* Are pregnant or breast-feeding.
* Abuse alcohol or drugs.
* Are taking, or have taken within 7 days of enrolling in the study, adefovir dipivoxil or drugs that may cause kidney problems, including aminoglycoside antibiotics, cidofovir, foscarnet, intravenous (IV) amphotericin B, IV pentamidine, IV vancomycin, and chemotherapy (e.g., cisplatin).
* Have any medical conditions or have had any medications that the study investigator believes will make him/her unsuitable for the study.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Foster City
country: United States
facility: Medical Information
state: California
Study officials:
References:
Clinical trial NCT06226389: Clinical Evaluation of Different Bulk-fill Composite Restorations on Posterior Teeth
Official title: 2-Year Clinical Evaluation of Different Bulk-fill Resin Composite Restorative Systems in Posterior Teeth
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Carious Teeth
Keywords: Bulk-fill composite, posterior cavities
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2024-01-26
Enrollment: 40
Sex: ALL
Minimum age (years): 25
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Different bulk-fill composites will be applied in different posterior cavities then compared

Detailed description: Patients must be in middle age(25-55) age,able to regularly follow up,not pregnant and at least have 4 carious molars

Eligibility criteria: Inclusion Criteria:

* at least 4 carious molars

Exclusion Criteria:

* pregnancy patient
* Not able to regularly follow up
* bad oral hygiene

Primary outcomes:
measure: Difference between baseline and after 2 years of evaluation of resin based composite
timeFrame: Baseline to 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Mansoura
country: Egypt
facility: Mansoura,Faculty of Dentistry
Study officials:
affiliation: Assistant lecturer
name: Asmaa S Elsaeed, Assistant lecturer
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03501589: Molecular Modulation of the Growth Plate
Official title: Molecular Modulation of the Growth Plate
Study type: OBSERVATIONAL
Overall status: ENROLLING_BY_INVITATION
Conditions: Growth Plate Injury
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2018-04-18
Enrollment: 100
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing surgery where growth plate cartilage or bone is removed as discarded tissue, waste, or surgical debris.

Brief summary: The researchers are trying to identify molecular mechanisms that control growth plate mediated limb growth and identify agents that can be used to enhance or slow growth.


Eligibility criteria: Inclusion Criteria:

* Skeletally immature children/adults undergoing surgical procedures where growth plate cartilage is removed as a normal part of their procedure; or patients undergoing surgical procedures where bone is removed as a normal part of their procedure.

Exclusion Criteria:

* Skeletally mature children/adults

Primary outcomes:
measure: RNA expression
timeFrame: End of Study (1/2019
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic'
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: A. Noelle Larson, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03322189: Pharmacogenomics Results Affect Patients' Plan of Care and Changes in Medication Prescription(s)
Official title: Medical Provider Experience and Assessment on Documenting Prescribing and Plan of Care Changes Due to Pharmacogenomics Testing
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Pharmacogenomic
Lead sponsor: Data Collection Analysis Business Management
Sponsor class: OTHER
Collaborators: name: PAS Research Services
First posted: 2017-10-26
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Current standard operating procedures for providers

Brief summary: Current providers' standard operating procedures on pharmacogenomic testing patients

Detailed description: The general design of this study is collecting data and reviewing Principal Investigators' Standard Operating Procedures on Pharmacogenomic testing and changes made to their specific SOP.

Eligibility criteria: Inclusion Criteria:

* Must be a Medical Practitioner

  * Medical Doctor (MD)
  * Doctor of Osteopathic (DO)
  * Physician Assistant (PA)
  * Advanced Practice Registered Nurse (APRN)
  * Nurse Practioner (NP)
* Must have a current standard operating procedure that includes obtaining/reviewing medical history.

Exclusion Criteria:

* Government-funded insurance data cannot be included in the study.

Primary outcomes:
measure: Provider Structures and Processes
timeFrame: 36 months
Secondary outcomes:
Other outcomes:
Locations:
city: Land O' Lakes
country: United States
facility: DCABM
state: Florida
Study officials:
References:
Clinical trial NCT00583089: Decompensation Detection Study
Official title: Decompensation Detection Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Heart Failure
Lead sponsor: Boston Scientific Corporation
Sponsor class: INDUSTRY
First posted: 2007-12-31
Enrollment: 699
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Heart failure patients

Brief summary: To gather data and analyze decompensation events.


Eligibility criteria: Inclusion Criteria:

* Patients implanted with an approved Guidant CRT-D HF device programmed to CRT therapy in VDD or DDD mode.
* Patients prescribed to the LATITUDE(R) system configured for at least weekly device interrogations and symptoms reporting.
* Patients willing to use the LATITUDE(R) enabled weight scale.

Exclusion Criteria:

* Patients that require adaptive rate pacing (rate-responsive modes).
* Patients that have received routinely scheduled intravenous inotropic therapy as part of their drug regimen within the past 90 days.
* Both

Primary outcomes:
measure: Data collection and analysis.
timeFrame: End of patient follow up.
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Washington University School of Medicine
name: Gregory Ewald, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Cardiology Associates of Northeast Arkansas
name: F. Roosevelt Gilliam, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00536289: Blunt Needles do Not Reduce Needlestick Injuries to Doctors During Suturing After Child-Birth
Official title: The Use of Blunt Needles Does Not Reduce Needlestick Injury During Obstetrical Laceration Repair
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Needlestick Injuries
Keywords: Blunt needles
obstetric lacerations
Needlestick injuries
Needlestick injuries to physicians
Lead sponsor: Medical University of South Carolina
Sponsor class: OTHER
First posted: 2007-09-27
Enrollment: 438
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The hypothesis for this study is that use of blunt tipped needles used during the repair of an episiotomy (tear in the vagina after childbirth) will result in fewer needlestick injuries to the surgeon.


Eligibility criteria: Inclusion Criteria:

* Obstetric laceration requiring suturing

Exclusion Criteria:

* \< 18 years old

Primary outcomes:
measure: Holes in surgeons gloves
timeFrame: After surgical repair
Secondary outcomes:
measure: Surgeon satisfaction with the needle assignment
timeFrame: After the surgical repair
Other outcomes:
Locations:
city: Charleston
country: United States
facility: Medical University of South Carolina
state: South Carolina
Study officials:
affiliation: Medical University of South Carolina
name: Scott A Sullivan, MD MSCR
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00219089: A Clinical Study to Evaluate the Safety and Efficacy of Aliskiren Alone and in Combination With Ramipril in Hypertensive, Diabetic Patients.
Official title: An Eight-week, Randomized, Double-blind, Parallel Group, Multicenter, Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Ramipril in Patients With Hypertension and Diabetes Mellitus
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Hypertension, Diabetes Mellitus
Keywords: Hypertension, aliskiren, blood pressure, diabetes mellitus, ramipril
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2005-09-22
Enrollment: 839
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To demonstrate the efficacy and safety of aliskiren given to patients with both hypertension and diabetes mellitus


Eligibility criteria: Inclusion Criteria

* Patients with essential hypertension
* Patients with a documented diagnosis of Type 1 or Type 2 diabetes mellitus.
* Patients who are eligible and able to participate in the study

Exclusion Criteria

* Severe hypertension
* History or evidence of a secondary form of hypertension
* History of hypertensive encephalopathy or cerebrovascular accident. Other protocol-defined exclusion criteria may apply

Primary outcomes:
measure: Change from baseline in mean sitting diastolic blood pressure after 8 weeks
Secondary outcomes:
measure: Change from baseline to week 4 endpoint in mean sitting diastolic blood pressure
measure: Change from baseline to week 8 endpoint in mean sitting systolic blood pressure
measure: Diastolic blood pressure less than 90 mmHg or reduction of 10 mmHg or greater from baseline after 8 weeks
Other outcomes:
Locations:
city: East Hanover
country: United States
facility: Novartis Pharmaceuticals
state: New Jersey
city: Investigative Centers
country: Germany
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References:
citation: Wang GM, Li LJ, Tang WL, Wright JM. Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev. 2020 Oct 22;10(10):CD012569. doi: 10.1002/14651858.CD012569.pub2.
citation: Uresin Y, Taylor AA, Kilo C, Tschope D, Santonastaso M, Ibram G, Fang H, Satlin A. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst. 2007 Dec;8(4):190-8. doi: 10.3317/jraas.2007.028.
Clinical trial NCT00579189: Phase III Study of an Otic Formulation in Acute Otitis Media With Tympanostomy Tubes
Official title: Safety and Efficacy of a Topical Otic Formulation in the Treatment of Acute Otitis Media With Otorrhea Through Tympanostomy Tubes (AOMT)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Acute Otitis Media
Keywords: ear tubes
ear drainage
ear infection
ear drops
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2007-12-21
Enrollment: 776
Sex: ALL
Minimum age (years): 6
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if a topical otic formulation is safe and effective in treating middle ear infections in patients with ear tubes.


Eligibility criteria: Inclusion Criteria:

* 6 months to 12 years old
* Ear tubes in one or both ears
* Ear drainage visible by the parent / guardian
* Ear drainage less than 21 days
* Ear tube may not be silver oxide, silver salt, t-type tube or long-shafted tube
* Patient may not have non-tube otorrhea
* Patient may not have had otic surgery other than tube placement in the last year
* Patient may not be a menarchal female
* Diabetic patients are not eligible
* Patient may not have any disease or condition that would negatively affect the conduct of the study
* Patient may not require any other systemic antimicrobial therapy during the study.
* Patient must meet certain medication washouts to be eligible
* Analgesic use (other than acetaminophen) is not allowed
* Patient may not be pre-disposed to neurosensory hearing loss
* Other protocol-defined inclusion criteria may apply

Exclusion Criteria:

* Age
* Other protocol-defined exclusion criteria may apply

Primary outcomes:
measure: Time to cessation of otorrhea as recorded by the parent or guardian via a patient diary
timeFrame: From baseline
Secondary outcomes:
measure: Clinical cure rate
timeFrame: From baseline
measure: Microbiological outcome
timeFrame: From baseline
measure: Treatment failures
timeFrame: From baseline
Other outcomes:
Locations:
Study officials:
affiliation: 1-888-451-3937
name: Contact Alcon Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT01611389: Minimizing Ventricular Pacing
Official title: Minimizing Right Ventricular Pacing in Dual-chamber Pacemaker Patients With Sinus Node Disease and First Degree Atrioventricular Block.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Sinus Node Disease.
First Degree Atrioventricular Block.
Lead sponsor: Military Institute od Medicine National Research Institute
Sponsor class: OTHER
First posted: 2012-06-05
Enrollment: 60
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The aim of this study is to evaluate the effect of minimizing right ventricular pacing in dual-chamber pacemaker patients with sinus node disease (SND) and first degree atrioventricular block (AVIB)on exercise capacity, quality of life and other heart failure measures.


Eligibility criteria: Inclusion Criteria:

* prolonged PQ interval \> 200 ms,
* percentage of right ventricular pacing with standard AV delay \> 90.

Exclusion Criteria:

* second or third degree atrioventricular block,
* permanent atrial fibrillation.

Primary outcomes:
measure: Oxygen uptake (cardiopulmonary exercise testing).
timeFrame: 3 months
Secondary outcomes:
measure: Left ventricular ejection fraction.
timeFrame: 3 months
measure: Quality of life
timeFrame: 3 months
measure: Arrhythmia
timeFrame: 3 months
measure: Ventilatory anaerobic threshold (cardiopulmonary exercise testing)
timeFrame: 3 months
measure: VE/VCO2 slope (cardiopulmonary exercise testing).
timeFrame: 3 months
Other outcomes:
Locations:
city: Warsaw
country: Poland
facility: Military Institute of Medicine
Study officials:
References:
Clinical trial NCT04078789: Evaluation of the Care Path of Patients Who Have Been Sexually Assaulted
Official title: Evaluation of the Care Path of Patients Who Have Been Sexually Assaulted, at Raymond Poincaré Hospital (France)
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Sexually Transmitted Diseases
Keywords: sex offenses
sexually transmitted diseases
traumatic injury
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2019-09-06
Enrollment: 250
Sex: ALL
Maximum age (years): 120
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Anyone declaring to be a victim of sexual assault and consulting in the medico-legal unit on judicial requisition (minors and adults).

Brief summary: The main objective of this study is to describe the care pathway of patients presenting in the medico-judicial unit of the Raymond Poincaré Hospital in Garches, France, following a complaint for sexual assault and suggest ways to improvement of the care adapted to the characteristics of the participants.

Detailed description: AS secondary objectives, the study aims to:

* Analyze the population of victims of sexual assault seen in consultation at the medico-judicial unit of Raymond Poincaré Hospital.
* Analyze the decision elements of the initiation of the post-exposure treatment and evaluate them against the recommendations.
* Analyze the data collected on the patients and their follow-up in consultation of infectious disease of the hospital of Garches following a sexual assault.
* Identify obstacles encountered by participants to follow the complete follow-up path.

For this purpose the data collection will be done initially within the forensic unit of Raymond Poincaré Hospital. Then, in a second step, the patients requiring the setting up of a post-exposure treatment, are addressed in the service of infectious diseases. The compilations of the data necessary for the study will then be continued until 3 months after the sexual assault.

For the collection of data, they will be based on the medical records of the victims.

Eligibility criteria: Inclusion Criteria:

* People declared being victim of sexual assault;
* Consult at medical-legal unit;
* Judicial requirement.

Exclusion Criteria:

- Absence of judicial requirement.

Primary outcomes:
measure: post-exposure prophylaxis requirement and surveillance termination
timeFrame: at 1 year
Secondary outcomes:
measure: Consulting at the medico-legal unit
timeFrame: at 1 year
measure: Follow-up in medico-legal unit
timeFrame: at 1 year
measure: Follow-up in the infectious diseases department
timeFrame: at 1 year
Other outcomes:
Locations:
Study officials:
affiliation: Unité médico-judiciaire (UMJ), Hôpital Raymond Poincaré, Garches, France
name: Céline Dufort, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Médecine aiguë spécialisée, Hôpital Raymond Poincaré, Garches, France
name: Dhiba Marigot-Outtandy, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01000389: A Clinical Trial of the Optimal Treatment Period and Long-term Efficacy of Functional Electrical Stimulation (FES) on Sleep Bruxism
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Temporomandibular Disorder
Headache
Lead sponsor: Medotech A/S
Sponsor class: INDUSTRY
First posted: 2009-10-23
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To investigate the effect of the treatment with Grindcare® on the parafunction of the muscles- and jaw activity (Bruxism) during sleep.


Eligibility criteria: Inclusion Criteria:

* RDC-TMD diagnosis
* Verified sleep bruxism
* More than 18 Years
* Signed ICF

Exclusion Criteria:

* Contraindication of concomitant medication and diseases judged by investigator
* Pacemaker

Primary outcomes:
measure: Reduction of number of grinds per hour per night
timeFrame: 7 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Aarhus
country: Denmark
facility: Odontologisk Institute
Study officials:
affiliation: Medotech A/S
name: Pernille Wendelboe, MsSc (Odont)
role: STUDY_CHAIR
References: